CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022
August 01 2022 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
leveraging the power of the mitochondria and the peptides encoded
in its genome to develop potential breakthrough therapeutics
targeting chronic and age-related diseases, announced today
that the company will release its 2022 second quarter
financial results after the market closes on Monday, August 15,
2022. Management will host a conference call and webcast at 5:00
p.m. ET (2:00 p.m. PT) on the same day to provide an update on the
company’s business.
Details for the Conference Call: Date: August
15, 2022Time: 5:00 p.m. ET (2:00 p.m. PT)
Conference Audio
- Dial-in U.S. and Canada: (877) 451-6152
- Dial-in International: (201) 389-0879
- Conference ID No.: 13730421
Webcast
- A simultaneous webcast of the call will be accessible via the
Investors section of the CohBar website at www.cohbar.com.
For individuals participating in the Investor Call or webcast,
please call or login to the conference audio approximately 10
minutes prior to its start.
An audio replay of the call will be available beginning at 8:00
p.m. Eastern Time on August 15, 2022, through 11:59 p.m. Eastern
Time on September 5, 2022. To access the recording please dial
(844) 512-2921 in the U.S. and Canada, or (412) 317-6671
internationally, and reference Conference ID# 13730421. The audio
recording will also be available at www.cohbar.com during the same
period.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company
leveraging the power of the mitochondria and the peptides encoded
in its genome to develop potential breakthrough therapeutics
targeting chronic and age-related diseases with limited to no
treatment options. CohBar has assembled the leading position in
exploring the mitochondrial genome and its utility for the
development of novel therapeutics, including world-renowned
expertise in mitochondrial biology, a broad intellectual property
estate, key opinion leaders and disciplined drug discovery and
development processes. CohBar is utilizing its Mito+ platform to
identify and develop modified versions of natural peptides called
analogs to treat a variety of serious conditions, with a focus on
diseases involving inflammation and fibrosis.
For additional company information, please visit www.cohbar.com
and engage with us on LinkedIn.
Contacts:
Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650)
445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Mar 2024 to Apr 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Apr 2023 to Apr 2024